JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Home・Akciju saraksts・Boston Scientific Corp.

Boston Scientific Corp.

Slēgts

SektorsVeselības aprūpe

55.97 -1.62

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

55.87

Max

56.99

Galvenie mērījumi
By Trading Economics
Ienākumi	-83M 672M
Pārdošana	-83M 5.2B
P/E Sektora vidējais	25.084 67.147
EPS	0.8
Peļņas marža	12.713
Darbinieki	59,000
EBITDA	116M 1.1B

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+56.76% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 29. jūl.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-1.5B 89B
Iepriekšējā atvēršanas cena	57.59
Iepriekšējā slēgšanas cena	55.97

Ziņu noskaņojums

By Acuity

51%

49%

281 / 347 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

102.95 / 104.93 Atbalsts un pretestība

Boston Scientific Corp. Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 22. apr. 11:22 UTC

Peļņas

Boston Scientific 1Q Net Grows Sharply, Company Cuts 2026 Adjusted EPS View

2026. g. 4. febr. 16:14 UTC

Peļņas

Galvenie tirgus virzītāji

Boston Scientific Plunges on Disappointing 1Q Outlook Despite 4Q Earnings Beat

2026. g. 4. febr. 12:13 UTC

Peļņas

Boston Scientific Sees More Growth after Earnings, Sales Rise

2026. g. 22. apr. 11:07 UTC

Peļņas

Boston Scientific 1Q Net Grows Sharply, Company Cuts 2026 Adj EPS View

2026. g. 22. apr. 10:32 UTC

Peļņas

Boston Scientific Now Sees 2026 Reported Sales Up 7%-8.5%, Organic Sales Up 6.5%-8% >BSX

2026. g. 22. apr. 10:31 UTC

Peļņas

Boston Scientific Sees 2Q Reported Sales Up 5.5%-7.5%, Organic Sales Up 5%-7% >BSX

2026. g. 22. apr. 10:30 UTC

Peļņas

Boston Scientific 1Q Organic Sales Up 9.4% >BSX

2026. g. 22. apr. 10:30 UTC

Peļņas

Boston Scientific 1Q Adj EPS 80c >BSX

2026. g. 22. apr. 10:30 UTC

Peļņas

Boston Scientific 1Q EPS 90c >BSX

2026. g. 22. apr. 10:30 UTC

Peļņas

Boston Scientific 1Q Sales $5.2B >BSX

2026. g. 22. apr. 10:30 UTC

Peļņas

Boston Scientific Sees 2Q Adj EPS 82c-Adj EPS 84c >BSX

2026. g. 22. apr. 10:30 UTC

Peļņas

Boston Scientific Sees FY Adj EPS $3.34-Adj EPS $3.41 >BSX

2026. g. 30. marts 15:34 UTC

Tirgus saruna

Boston Scientific Faces Some Slowing Growth Trends -- Market Talk

2026. g. 4. febr. 21:41 UTC

Peļņas

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

2026. g. 4. febr. 19:38 UTC

Peļņas

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

2026. g. 4. febr. 17:32 UTC

Peļņas

These Stocks Are Today's Movers: AMD, AbbVie, Eli Lilly, Boston Scientific, MP Materials, Super Micro, Silicon Labs, Uber, and More -- Barrons.com

2026. g. 4. febr. 15:30 UTC

Peļņas

Boston Scientific Earnings Beat Estimates. It's the Worst Stock in the S&P 500 Today. -- Barrons.com

2026. g. 4. febr. 15:29 UTC

Peļņas

These Stocks Are Today's Movers: AMD, Eli Lilly, AbbVie, Uber, Super Micro, Enphase, Boston Scientific, and More -- Barrons.com

2026. g. 4. febr. 14:06 UTC

Peļņas

Boston Scientific Profit, Sales Rise but Issues Soft Guidance -- Update

2026. g. 4. febr. 13:58 UTC

Peļņas

Boston Scientific Earnings Beat Expectations. Why the Stock Is Down Sharply. -- Barrons.com

2026. g. 4. febr. 13:12 UTC

Peļņas

Boston Scientific Earnings Beat Expectations. Why the Stock Is Down Sharply. -- Barrons.com

2026. g. 4. febr. 11:32 UTC

Peļņas

Boston Scientific Sees 2026 Sales Up 10.5%-11.5%, Organic Sales Up 10%-11% >BSX

2026. g. 4. febr. 11:31 UTC

Peļņas

Boston Scientific Sees 1Q Sales Up 10.5%-12%, Organic Sales Up 8.5%-10% >BSX

2026. g. 4. febr. 11:30 UTC

Peļņas

Boston Scientific 4Q Organic Sales Up 12.7% >BSX

2026. g. 4. febr. 11:30 UTC

Peļņas

Boston Scientific Sees 2026 Adj EPS $3.43-Adj EPS $3.49 >BSX

2026. g. 4. febr. 11:30 UTC

Peļņas

Boston Scientific Sees 1Q Adj EPS 78c-Adj EPS 80c >BSX

2026. g. 4. febr. 11:30 UTC

Peļņas

Boston Scientific 4Q Adj EPS 80c >BSX

2026. g. 4. febr. 11:30 UTC

Peļņas

Boston Scientific 4Q Sales $5.29B >BSX

2026. g. 4. febr. 11:30 UTC

Peļņas

Boston Scientific 4Q EPS 45c >BSX

2026. g. 24. janv. 06:18 UTC

Iegādes, apvienošanās, pārņemšana

Our Boston Scientific Pick Has Stumbled. Acquiring Penumbra Will Help the Stock. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Boston Scientific Corp. Prognoze

Cenas mērķis

By TipRanks

56.76% augšup

Prognoze 12 mēnešiem

Vidējais 89.12 USD 56.76%

Augstākais 118 USD

Zemākais 71 USD

Pamatojoties uz 27 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Boston Scientific Corp. — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

27 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 27 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Boston Scientific Corp. — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

102.95 / 104.93Atbalsts un pretestība

All events are bullish.

Recent bearish events outweigh bullish events.

There are no events.

Noskaņojums

By Acuity

281 / 347 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.